Phytotherapy and Plant-derived Bioactive Compounds in Schizophrenia: Preclinical Evidence, Clinical Trials, and Mechanistic Insights: Review
Background: Schizophrenia is a chronic and debilitating neuropsychiatric disorder characterised by positive symptoms, negative symptoms, and cognitive impairments that significantly affect quality of life and functional outcomes. Although antipsychotic medications remain the cornerstone of treatment, their limited efficacy against negative and cognitive symptoms and their associated adverse effects have prompted interest in complementary therapeutic approaches such as phytotherapy. Aim: This review aims to critically evaluate the current preclinical and clinical evidence regarding the therapeutic potential of phytotherapeutic agents and plant-derived bioactive compounds in the management of schizophrenia. Methods: Relevant literature on phytotherapy in schizophrenia was examined, focusing on preclinical studies, clinical trials, and mechanistic investigations. Key botanical extracts and phytochemicals, including Withania somnifera, Ginkgo biloba, Curcuma longa, Panax ginseng, Bacopa monnieri, Cannabidiol, and Centella asiatica, were assessed for their pharmacological mechanisms, efficacy, safety, and translational relevance. Results: The reviewed evidence indicates that several phytotherapeutic agents exhibit antioxidant, anti-inflammatory, neuroprotective, and neuromodulatory properties that target multiple pathways implicated in schizophrenia pathophysiology. Clinical and preclinical studies suggest potential benefits in improving negative symptoms, cognitive deficits, and overall symptom management. Among the reviewed agents, Cannabidiol and G. biloba demonstrated the strongest clinical support, while other compounds showed promising but preliminary outcomes. Conclusion: Phytotherapy represents a promising adjunctive strategy for schizophrenia by targeting pathophysiological mechanisms inadequately addressed by conventional antipsychotics. However, methodological limitations, including small sample sizes, heterogeneous study designs, and a lack o